Iressa Promotion Halted; AstraZeneca To Highlight Tarceva Survival Benefit

 
• By Andrew Kasper

Gefitinib fails to demonstrate a survival benefit in the Iressa Survival Evaluation in Lung cancer confirmatory trial. AstraZeneca will meet with FDA to determine whether accelerated approval licensure of Iressa will be withdrawn, CEO McKillop says.

More from Archive

More from Pink Sheet